Avatar universal

Replicor to Make Three Presentations at EASL 2016

NEW YORK, April 4, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that it will present three abstracts at the EASL 2016 annual meeting to be held April 13-26, 2017 in Barcelona, Spain.
These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:
·        Updated clinical data from the ongoing REP 301 study assessing the safety and efficacy of REP 2139-Ca combined with pegylated interferon in patients with hepatitis B / hepatitis D co-infection (poster FRI-105).
·        In vivo antiviral activity of REP 2139-Ca combined with tenofovir disoproxil fumarate and entecavir (poster THU-177).
·        Immunostimulatory properties of REP 2139 and other NAP compounds (poster THU-204).
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations.  For the 2016 EASL Meeting: http://ilc-congress.eu/.
1 Responses
Sort by: Helpful Oldest Newest
Avatar universal
its like dream. a cure for hep b
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
Can I get HIV from surfaces, like toilet seats?